Novotech, a Sydney, Australia-based biotech specialist clinical research organization (CRO), received an investment from GIC, Teasek and TPG.
The amount of the deal was not disclosed.
The company intends to use the funds to accelerate its growth and pursue M&A opportunities.
Led by CEO John Moller, Novotech is a full-service clinical research organization (CRO) and scientific advisory company used by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, it provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Today, the company has a global footprint across the Asia-Pacific region, North America and Europe, and partnerships with more than 5,000 trial sites.
FinSMEs
31/03/2025